SynopsisMylotarg is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. The global Mylotarg market was valued at US$ 214.3 million in 2023 and is anticipated to reach US$ 179.5 million b.....
SynopsisMidostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. The global Midostaurin market was valued at US$ 127......
SynopsisMidostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. The global Midostaurin Drugs market was valued at US.....
SynopsisIvosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Ivosidenib market was valued at US$ 175.3 million in 2023 and is anticipated to reach US$ 238.5 .....
SynopsisIvosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Ivosidenib Drugs market was valued at US$ 175.3 million in 2023 and is anticipated to reach US$ .....
SynopsisTibsovo is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Tibsovo market was valued at US$ 175.3 million in 2023 and is anticipated to reach US$ 238.5 millio.....
SynopsisVYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin market was valued at US$ 128 million in 2023 and is anticipated to reach US$ 184 million by 2030, witnessi.....
SynopsisVYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin Drugs market was valued at US$ 128 million in 2023 and is anticipated to reach US$ 184 million by 2030, wi.....
SynopsisVYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Vyxeos market was valued at US$ 128 million in 2023 and is anticipated to reach US$ 184 million by 2030, witnessing a CAGR of 5.3% dur.....
SynopsisAcute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia .....
